Molecular Diagnostic Business Development Initiative

AccuGenomics is interested in partnering with companies on the following initiatives:

  • Commercialize and launch – FDA approved proprietary Leukemia and Lung cancer tests.
  • Collaborate with Biopharmaceutical Companies in the Development of gene expression Companion Diagnostics to assist with treatment decisions based on the efficacy and/or safety of a specific compound for specific population.
  • Identify and Develop new molecular diagnostic tests utilizing our SNAQ Technology through collaborations by translating a biomarker to a diagnostic.

Contact our Business Development Team (development@accugenomics.com) for further information as it relates to partnering opportunities.